Libo Zhang and Sylvain Baruchel
Significant advances have been made to understand the association between ALK genetic aberrations and disease prognosis in neuroblastoma. ALK targeted therapies are evolving quickly and several randomized controlled trials of ALK inhibitors are underway or nearing completion in adult cancers. Ongoing research will bring new challenges and newer technologies to fully define the pathogenic and prognostic alterations, to stratify the risk of recurrence or progression, and to develop optimal monitoring and treatment strategies in this malignancy.
Compartilhe este artigo
English 
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Hindi 